Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Earnings Results, Misses Expectations By $2.78 EPS

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings data on Wednesday. The company reported ($3.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78), FiscalAI reports. The business had revenue of $0.79 million for the quarter, compared to analyst estimates of $0.74 million.

Armata Pharmaceuticals Stock Performance

ARMP stock traded down $0.13 during mid-day trading on Thursday, reaching $8.69. 37,984 shares of the stock traded hands, compared to its average volume of 55,165. Armata Pharmaceuticals has a one year low of $1.17 and a one year high of $16.34. The stock has a market capitalization of $318.87 million, a PE ratio of -1.81 and a beta of 1.31. The business has a 50-day moving average price of $10.50 and a two-hundred day moving average price of $8.12.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ARMP. Jane Street Group LLC bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth about $108,000. Millennium Management LLC bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth about $164,000. OMERS ADMINISTRATION Corp bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth about $177,000. Goldman Sachs Group Inc. bought a new position in shares of Armata Pharmaceuticals in the fourth quarter worth about $284,000. Finally, State Street Corp grew its holdings in shares of Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after purchasing an additional 10,500 shares during the last quarter. Institutional investors own 3.57% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their price objective on shares of Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $15.00.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.